Search the Newsreel

The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call

The Top 5 Analyst Questions From Halozyme Therapeutics's Q2 Earnings Call Halozyme Therapeutics delivered a notably positive second quarter, as evidenced by the strong market reaction and management's attribution of outperformance to surging royalty revenue and a wave of new collaboration agreements. CEO Helen …

Wedge Capital Management L L P NC Invests $31.61 Million in Halozyme Therapeutics, Inc. $HALO

Wedge Capital Management L L P NC has invested $31.61 million in Halozyme Therapeutics, Inc., acquiring 403,824 shares. Halozyme Therapeutics, a biopharmaceutical company, reported strong quarterly results with EPS of $2.28 and revenue of $481 million, exceeding analyst expectations. The company maintains a "Moderate …

Handelsbanken Fonder AB Grows Stake in Halozyme Therapeutics, Inc. $HALO

Handelsbanken Fonder AB significantly increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 28.1% in Q2 2026, now holding 631,899 shares valued at $49.5 million. This move is part of broader institutional investment, with various firms adjusting their holdings, and insiders also making transactions. …

Halozyme Therapeutics, Inc. (HALO) stock price, news, quote and history

Halozyme director Connaughton sells $167,152 in shares

Halozyme Therapeutics director Bernadette Connaughton sold 1,626 shares of company stock for a total of $167,152 on August 10, 2026, at a price of $102.8 per share. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in May 2025. Following the …

Halozyme Therapeutics (HALO) director sells 1,626 shares in Rule 10b5-1 plan trade

Halozyme Therapeutics (HALO) director Bernadette Connaughton sold 1,626 shares of common stock at $102.80 per share on August 10, 2026, under a Rule 10b5-1 trading plan adopted in May 2025. Following this transaction, she directly holds 40,418 shares. The sale, valued at approximately $167,000, …

Halozyme Therapeutics (HALO) affiliate plans stock option-related share sales in Form 144

Halozyme Therapeutics (HALO) filed a Form 144, indicating an affiliate's intention to sell common stock through Morgan Stanley Smith Barney LLC. These planned sales are linked to stock option exercises set for August 11, 2026, involving transactions for 32,659, 5,277, and 3,766 shares of …

HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance

HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) announced better-than-expected revenue in Q2 CY2026, with sales up 47.7% year on year to $481 million. The company's full-year revenue guidance of $1.87 billion at …

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Moderate Buy" by Analysts

Halozyme Therapeutics (NASDAQ:HALO) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $91.20, though some targets have been raised to $115. The company exceeded quarterly expectations with $2.28 EPS and $481 million in revenue, leading to positive …

What Halozyme Therapeutics (HALO) Guidance Raise Means For Valuation

Halozyme Therapeutics (HALO) recently reported strong Q2 earnings, with revenue of US$481 million and net income of US$229.91 million, leading to raised full-year revenue guidance and new collaboration agreements. Despite a significant 1-year share price return of 63.17%, the company faces mixed valuation signals, …

Halozyme Therapeutics (HALO) insider schedules 1,626-share stock sale via trading plan

Halozyme Therapeutics insider Bernadette Connaughton plans to sell 1,626 shares of common stock, valued at $167,673.12, through Morgan Stanley Smith Barney LLC on August 10, 2026. These shares originated from Restricted Stock Units granted in April 2025. The filing also details prior sales under …

Gradient Investments LLC Makes New Investment in Halozyme Therapeutics, Inc. $HALO

Gradient Investments LLC has purchased a new stake in Halozyme Therapeutics, Inc. ($HALO), acquiring 16,437 shares valued at approximately $1.29 million. This investment comes as Halozyme reported a strong second quarter with significant revenue growth and raised its 2026 guidance, attracting positive analyst sentiment. …

Earnings Update: Halozyme Therapeutics, Inc. Beat Earnings And Now Analysts Have New Forecasts For This Year

Halozyme Therapeutics, Inc. reported a strong quarter, exceeding analysts' earnings expectations. Following these results, analysts have updated their financial forecasts for the current year, indicating a positive outlook for the company's performance. This update reflects increased confidence in Halozyme's financial trajectory.

Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Biotech Powerhouse with Robust Revenue Growth and Strong Analyst Support

Halozyme Therapeutics (HALO) Is Up 24.9% After Record Q2, Higher 2026 Guidance And New ENHANZE Deals - Has The Bull Case Changed?

Halozyme Therapeutics reported record second-quarter results with revenue up to US$481 million and net income of US$229.91 million, leading to increased full-year 2026 revenue guidance. The company also accelerated share buybacks and secured new ENHANZE collaborations, reinforcing its royalty-led business model. While these achievements …

Halozyme Therapeutics (HALO) Stock Looks Expensive At Today’s Price

Halozyme Therapeutics (HALO) has seen a 106.2% return over five years, but its current valuation suggests the stock is expensive, trading at 29.2x earnings compared to a fair P/E of 20.1x. Despite strong financial results and collaboration agreements, the company's P/E ratio is above …

Halozyme Therapeutics (HALO) Is Up 24.9% After Raising 2026 Revenue Outlook and Boosting Buybacks

Halozyme Therapeutics reported record second-quarter results with revenue at US$481 million and net income at US$229.91 million, leading to a 24.9% stock increase. The company raised its 2026 revenue guidance to US$1.84 billion - US$1.91 billion and boosted share buybacks by an additional US$175.01 …

Halozyme Therapeutics, Inc. Stock 12‑Month Price Target Raised to $99.56, Implies 16% Upside

Analysts have raised the average 12-month price target for Halozyme Therapeutics, Inc. (HALO) stock to $99.56, up from $86.89. This new target suggests a potential upside of approximately 16% from its recent closing price. The consensus rating among 11 analysts remains a "Buy," with …

Is Halozyme Therapeutics (HALO) Fairly Valued As Earnings Beat And Guidance Rise?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Halozyme earnings beat and guidance hike reshape the story Halozyme Therapeutics (HALO) just put fresh numbers on the table, reporting second quarter 2026 results, raising …

Halozyme (HALO) Stock Rallies As Royalties Surge And Guidance Climbs

Halozyme Therapeutics (HALO) stock rallied 20% after reporting strong Q2 2026 earnings, exceeding revenue and EPS expectations, driven by a 47.5% increase in total revenue and 39.2% increase in net income. The company also raised its full-year 2026 revenue and earnings guidance, reinforcing its …

Assenagon Asset Management S.A. Has $78.09 Million Position in Halozyme Therapeutics, Inc. $HALO

Assenagon Asset Management S.A. significantly increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4,578.9% in the second quarter, now holding 997,643 shares valued at $78.1 million. This increase follows Halozyme's strong second-quarter results, which exceeded analyst expectations with adjusted EPS of $2.28 and …

Halozyme Therapeutics (NASDAQ:HALO) Upgraded to Strong-Buy at Wall Street Zen

Halozyme Therapeutics (NASDAQ:HALO) was upgraded to a "strong-buy" rating by Wall Street Zen following impressive quarterly results where EPS and revenue significantly beat estimates. The company also raised its 2026 guidance, driven by strong royalty growth and new ENHANZE and Hypercon agreements. Despite some …

Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know

Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know What Happened? Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 18.1% in the afternoon session after the company reported strong second-quarter earnings that surpassed analyst expectations and raised its full-year financial guidance. …

Halozyme Therapeutics Inc (HALO) (Q2 2026) Earnings Call Highlights: Record Revenue and Royalty ...

This article first appeared on GuruFocus. Total Revenue: Increased 48% year-over-year to $481 million. Royalty Revenue: Record growth of 50% year-over-year to $308 million. Adjusted EBITDA: Increased 46% to $328.8 million, with a margin of more than 65%. Net Income: Increased 39% to $229.9 …

HALO Surges As Halozyme Hikes 2026 EPS And Revenue Outlook

Why Halozyme, An IBD 50 Stock, Just Hit A Record High In Bullish Volume

Halozyme stock rocketed to a record high Friday as its newer Enhanze-tied products start driving incremental growth. Continue Reading

Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up

Halozyme Therapeutics HALO Surges After Big Earnings Beat And Guidance Hike

Halozyme Therapeutics (HALO) surged by 19.44% after reporting Q2 earnings that significantly beat expectations, with non-GAAP EPS at $2.28 and revenue at $481M. The company also raised its 2026 non-GAAP EPS and revenue guidance above Street estimates, driven by strong royalty growth and new …

Halozyme Therapeutics (NASDAQ:HALO) Upgraded to "Outperform" at Leerink Partners

Leerink Partners has upgraded Halozyme Therapeutics (NASDAQ:HALO) from "market perform" to "outperform," setting a $110 price target. This upgrade follows Halozyme's strong quarterly results, with revenue up 47.7% year-over-year and EPS significantly beating estimates, leading management to raise its fiscal 2026 outlook. The company …

HALOZYME THERAPEUTICS, INC. : LEERINK PARTNERS RAISES TO OUTPERFORM FROM MARKET PERFORM; RAISES TARGET PRICE TO $110 FROM $83

Leerink Partners has upgraded Halozyme Therapeutics, Inc. (HALO.O) from Market Perform to Outperform. The firm also increased its target price for Halozyme Therapeutics to $110, up from the previous $83. This suggests a more positive outlook on the company's stock performance.

Halozyme Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:HALO) 2026-08-07

Halozyme Therapeutics, Inc. (HALO) has published its Q2 2026 earnings call presentation, reporting significant financial beats. The company's EPS of $2.28 surpassed estimates by $0.46, and revenue reached $481.00M, exceeding expectations by $78.72M and showing a 47.67% year-over-year increase. This presentation was released in …

HALOZYME THERAPEUTICS, INC. 2026: Revenue $481M, EPS $1.9— 10-Q Summary

HALOZYME THERAPEUTICS, INC. reported strong financial results for the 2026 quarter, with revenue reaching $481 million and diluted EPS of $1.9. This growth was primarily driven by increased royalties, particularly from products like DARZALEX SC and VYVGART Hytrulo, and significant growth in bulk rHuPH20 …

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Halozyme Therapeutics (HALO) reported revenue of $481 million, up 47.7% over the same period last year. EPS came in at $2.28, compared to $1.54 in the year-ago quarter. The reported revenue represents a surprise of +17.44% over the …